Middle dose level:1.0×10^6 UCAR+ T Cells/kg

2 trials

Sponsors

Zhongshan People's Hospital

Conditions

Malignant head and neck squamous cell carcinomaR/RMultiple myeloma

Early Phase 1

To evaluate the safety and tolerability of CD19-BCMA UCAR-T cell injection in patients with relapsed or refractory multiple myeloma

RecruitingChiCTR2000039852

Zhongshan People's HospitalR/RMultiple myeloma

Start: 2021-01-01Updated: 2021-02-22

A clinical study to evaluate the safety and tolerability of AMT-116 UCAR-T cell injection in subjects with malignant head and neck squamous cell carcinoma

RecruitingChiCTR2000039850

Zhongshan People's HospitalMalignant head and neck squamous cell carcinoma

Start: 2021-01-01Updated: 2021-02-22